The Swedish agency decided to temporarily stop using the Moderna Covid-19 vaccine until 1 December. Credit: Spencer Davis / Pixabay.

Denmark and Sweden have reportedly decided to temporarily halt the use of Moderna’s mRNA Covid-19 vaccine, Spikevax, for younger age groups due to reports of possible rare side effects.

The Public Health Agency of Sweden stated that recent data points to an increased risk in the inflammation of the heart muscle (myocarditis) and the inflammation of the pericardium (pericarditis).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It has decided to pause the use of Spikevax for people born in and after 1991 for cautionary reasons.

The agency said in a statement: “New preliminary analyses from Swedish and Nordic data sources suggest that the link is particularly clear when it comes to Moderna’s vaccine Spikevax, especially after the second dose. The increase in risk is seen within four weeks of vaccination, mainly within the first two weeks.”

The usage of the Moderna Covid-19 vaccine will be temporarily halted until 1 December, as reported by Business Insider.

Meanwhile, Denmark has also decided to halt using the Moderna vaccine for people aged below 18 as a precautionary principle.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, the country has been using the Pfizer/BioNTech‘s Covid-19 vaccine as its main option for 12 to 17 aged individuals.

Now, both countries are recommending the use of their vaccine, Comirnaty, instead of Moderna’s vaccine.

The European Medicines Agency (EMA) authorised the booster shot of Moderna’s Covid-19 vaccine, Spikevax, for immunocompromised individuals aged 12 years and above.

In a separate development, Spain granted approval for the booster shots of vaccines from Pfizer and Moderna for individuals aged 70 years and above to be administered from six months after they receive their second dose.